- Home
- IMCC vs KZIA Comparison
IMCC vs KZIA Comparison
Compare IMCC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- KZIA
- Stock Information
- Founded
- IMCC 1980
- KZIA 1994
- Country
- IMCC Israel
- KZIA Australia
- Employees
- IMCC N/A
- KZIA N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- KZIA Health Care
- Exchange
- IMCC Nasdaq
- KZIA Nasdaq
- Market Cap
- IMCC 12.0M
- KZIA 5.1M
- IPO Year
- IMCC N/A
- KZIA 1999
- Fundamental
- Price
- IMCC $3.07
- KZIA $10.77
- Analyst Decision
- IMCC
- KZIA Strong Buy
- Analyst Count
- IMCC 0
- KZIA 2
- Target Price
- IMCC N/A
- KZIA $14.00
- AVG Volume (30 Days)
- IMCC 155.5K
- KZIA 692.0K
- Earning Date
- IMCC 08-13-2025
- KZIA 07-22-2025
- Dividend Yield
- IMCC N/A
- KZIA N/A
- EPS Growth
- IMCC N/A
- KZIA N/A
- EPS
- IMCC N/A
- KZIA N/A
- Revenue
- IMCC $37,894,737.00
- KZIA $1,549,158.00
- Revenue This Year
- IMCC $47.12
- KZIA N/A
- Revenue Next Year
- IMCC $12.83
- KZIA N/A
- P/E Ratio
- IMCC N/A
- KZIA N/A
- Revenue Growth
- IMCC 12.68
- KZIA 248983.08
- 52 Week Low
- IMCC $1.29
- KZIA $2.86
- 52 Week High
- IMCC $7.12
- KZIA $40.75
- Technical
- Relative Strength Index (RSI)
- IMCC 58.57
- KZIA 75.96
- Support Level
- IMCC $2.76
- KZIA $5.86
- Resistance Level
- IMCC $3.75
- KZIA $12.00
- Average True Range (ATR)
- IMCC 0.35
- KZIA 1.03
- MACD
- IMCC 0.04
- KZIA 0.41
- Stochastic Oscillator
- IMCC 78.69
- KZIA 90.23
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.